Why is Alembic Pharma falling/rising?

Recent Price Performance and Market Comparison

Over the past week, Alembic Pharma’s stock has fallen by 1.94%, contrasting sharply with the Sensex’s modest gain of 0.13%. This negative momentum extends over longer periods, with the stock declining 4.35% in the last month while the benchmark rose 0.77%. Year-to-date figures reveal a more pronounced divergence: Alembic Pharma has lost 18.47% of its value, whereas the Sensex has advanced by 9.05%. Over the last year, the stock’s return stands at -18.74%, significantly underperforming the Sensex’s 3.75% gain. Even over three years, despite a positive 47.32% return, Alembic Pharma only marginally outpaced the Sensex’s 37.89%, and its five-year performance remains disappointing with a 19.72% loss compared to the Sensex’s robust 84.19% growth.

Technical Indicators and Trading Activity

On the technical front, Alembic Pharma is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This positioning typically signals bearish sentiment among traders and investors. The stock has also underperformed its sector by 1.29% today and has experienced a consecutive four-day decline, cumulatively losing 2.6% in that period. Furthermore, investor participation appears to be waning, with delivery volumes on 12 Dec falling by 16.32% compared to the five-day average, indicating reduced buying interest. Despite this, liquidity remains adequate for moderate trade sizes, suggesting that the stock remains accessible to market participants.

Fundamental Strengths Amidst Weak Price Action

Despite the recent price weakness, Alembic Pharma exhibits some fundamental strengths. The company maintains a low Debt to EBITDA ratio of 0.90 times, indicating a strong capacity to service its debt obligations. Its latest quarterly results, reported on 25 Sep, showed robust operating profit to interest coverage at 13.03 times and a PBDIT of ₹315.69 crores, the highest recorded. Profit before tax excluding other income grew impressively by 43.76% to ₹216.81 crores. The company’s return on capital employed (ROCE) stands at a respectable 12.6%, and it trades at an attractive valuation with an enterprise value to capital employed ratio of 2.7, suggesting it is priced at a discount relative to its peers’ historical averages. Institutional investors hold a significant 20.34% stake, reflecting confidence from sophisticated market participants who typically conduct thorough fundamental analysis.

Challenges Weighing on Long-Term Prospects

Nevertheless, the stock’s long-term growth trajectory raises concerns. Operating profit has declined at an annualised rate of 8.80% over the past five years, signalling persistent challenges in expanding profitability. This sluggish growth is mirrored in the stock’s underperformance relative to broader market indices and sector benchmarks. Over the last one year and three months, Alembic Pharma has lagged behind the BSE500 index, reinforcing the narrative of below-par returns. Additionally, profits have marginally fallen by 0.2% over the past year, which, coupled with the negative share price performance, dampens investor enthusiasm.

Investor Takeaway

In summary, Alembic Pharmaceuticals’ recent share price decline is primarily attributable to its sustained underperformance against key benchmarks and a lack of positive momentum in trading activity. While the company’s fundamentals, including debt management and recent quarterly profitability, remain sound, the subdued long-term growth and disappointing returns have weighed heavily on investor sentiment. The stock’s valuation discount and institutional backing may offer some support, but the prevailing technical weakness and falling investor participation suggest caution. Investors should carefully weigh these factors against their investment horizon and risk appetite before considering exposure to Alembic Pharma.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →